Biotech Values

[DewDiligence]

ELN/BIIB – Lehman has cut the projected 2009 Tysabri growth rate by 2/3. Instead of 400 net new patients per week, they now expect only 140:

http://siliconinvestor.advfn.com/readmsg.aspx?msgid=24818487


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”